Structure Therapeutics (NASDAQ:GPCR) was given a new $50.00 price target on by analysts at Stifel Nicolaus.
Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Structure Therapeutics (NASDAQ:GPCR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts [Yahoo! Finance]
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights